Financial PerformanceFor the quarter, the company reported no revenues and a net loss of $0.13 per diluted share, compared to consensus estimated net loss of $0.12 per share.
Investor ConfidenceThere is a lack of investor confidence that higher dose data will show improved results, contributing to the stock's decline.
Market ReactionThe significant drop in CRVS shares is seen as an overreaction, potentially due to market disappointment with soquel's efficacy compared to Dupixent.